Income from Continuous Operations: A company's total income or loss before discontinued operations, extraordinary items, preferred stock dividends and accounting change.
Nuvectis Pharma, Inc. (NVCT) had Income from Continuous Operations of $-7.46M for the most recently reported fiscal quarter, ending 2025-09-30.
| Income Statement Financials | |
-- |
|
$-9.89M |
|
-- |
|
-- |
|
$7.79M |
|
$-7.79M |
|
$0.33M |
|
$-7.46M |
|
$-7.46M |
|
$-7.46M |
|
|
Income from Continuous Operations |
$-7.46M |
$-7.46M |
|
$-7.46M |
|
$-7.79M |
|
$-7.79M |
|
22.72M |
|
22.72M |
|
$-0.44 |
|
$-0.44 |
|
| Balance Sheet Financials | |
$35.59M |
|
-- |
|
-- |
|
$35.59M |
|
$11.58M |
|
-- |
|
-- |
|
$11.58M |
|
$24.01M |
|
$24.01M |
|
$24.01M |
|
25.64M |
|
| Cash Flow Statement Financials | |
$-12.04M |
|
-- |
|
$28.94M |
|
$18.53M |
|
$35.44M |
|
$16.91M |
|
$4.56M |
|
-- |
|
-- |
|
| Fundamental Metrics & Ratios | |
3.07 |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
$-12.04M |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-31.08% |
|
-31.08% |
|
-20.97% |
|
-31.08% |
|
$0.94 |
|
$-0.53 |
|
$-0.53 |
|